Solifenacin Treatment Of Patients With Severe Overactive Bladder Symptoms: Effects On Diary-Based And Patient-Reported Outcomes

Main Category: Urology / Nephrology
Article Date: 27 Oct 2008 - 4:00 PDT

email to a friend   printer friendly   opinions  

PHILADELPHIA, PA, USA (UroToday.com) - This was a post hoc analysis of solifenacin Efficacy and Safety in Patients with Urgency Study (VENUS) to determine patients with severe OAB symptoms at baseline.

It was a randomized, double-blind placebo-controlled 12 week study of solifenacin (5 or 10 mg/day of flexible dosing). The primary end-point was change in urgency episodes/24 hours from baseline to study end using 3-day bladder diaries. Secondary endpoints included mean change in warning time (WT) and patient related outcomes (PRO) measures. 22% of subjects had severe OAB symptoms. In the severe OAB subgroup, subjects receiving solifenacin showed marked median changes in WT compared with placebo. In this severe subgroup; solifenacin also improved patient perception of their symptoms and all PRO measures.

A limitation of this analysis is the lack of power to detect treatment differences among severe OAB patients.

Presented by J. A. Dahl, R. W. Lobel, S. Forero-Schwanhaeuser, and T. Lennon-Giles, at the 39th Annual Conference of the Society of Urologic Nurses and Associates - October 3 - 6, 2008 - Philadelphia, PA, USA

Reported by UroToday.com Contributing Editor Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDB

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations